Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Abstract Background Intrinsic or acquired resistance to HER2-targeted therapy is often a problem when small molecule tyrosine kinase inhibitors or antibodies are used to treat patients with HER2 positive breast cancer. Therefore, the identification of new targets and therapies for this patient group...

Full description

Bibliographic Details
Main Authors: Magdalena Keller, Katharina Rohlf, Annika Glotzbach, Gregor Leonhardt, Simon Lüke, Katharina Derksen, Özlem Demirci, Defne Göçener, Mohammad AlWahsh, Jörg Lambert, Cecilia Lindskog, Marcus Schmidt, Walburgis Brenner, Matthias Baumann, Eldar Zent, Mia-Lisa Zischinsky, Birte Hellwig, Katrin Madjar, Jörg Rahnenführer, Nina Overbeck, Jörg Reinders, Cristina Cadenas, Jan G. Hengstler, Karolina Edlund, Rosemarie Marchan
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Breast cancer
HER2 positive breast cancer
Choline metabolism
HER2-targeting therapy resistance
GPCPD1
Online Access:https://doi.org/10.1186/s13046-022-02578-w

Internet

https://doi.org/10.1186/s13046-022-02578-w

Similar Items